Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant965 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,240 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02043665 | CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)(STORM) | completed | Phase 1 | 85 | ViralyticsINDUSTRY | 3 | May 6, 2023 | clinicaltrials |
| NCT00716625 | Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) | completed | — | 1,674 | PfizerINDUSTRY | 0 | May 3, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02850809 | Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors(RF-REIN) | completed | — | 310 | University Hospital, BordeauxOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05540847 | Comparison of Interfascial Injection Versus Subpectineal Injection on Ultrasound-guided Obturator Nerve Block | completed | N/A | 60 | Diskapi Teaching and Research HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05823545 | Assessment of Complications in Patients Who Underwent LPN According to the CCI | completed | — | 62 | Samsun Liv HospitalOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02695771 | The Bladder Instillation Comparison Study(BIC) | completed | Phase 3 | 101 | Corewell Health WestOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT02371447 | VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 39 | Swiss Cancer InstituteOTHER | 2 | Apr 13, 2023 | clinicaltrials |
| NCT03472274 | Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)(DUTRENEO) | completed | Phase 2 | 101 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT02853344 | Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | completed | Phase 2 | 275 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 11, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04076787 | Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib | completed | — | 1,769 | PfizerINDUSTRY | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04487457 | Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy(CINECI) | completed | — | 31 | University Hospital, ToursOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT02732665 | Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma | completed | — | 50 | Jens NielsenOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05799456 | Glycosaminoglycan Scores as Early Detection Biomarkers in Bladder Urothelial Carcinoma | completed | — | 106 | Jens NielsenOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT04209192 | Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB) | completed | Phase 2 | 75 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05324033 | Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer | completed | — | 30 | Helwan UniversityOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
| NCT02732652 | Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma | completed | — | 72 | Chalmers University of TechnologyOTHER | 1 | Mar 22, 2023 | clinicaltrials |
| NCT02019693 | A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2023 | clinicaltrials |
| NCT03428217 | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma(CANTATA) | completed | Phase 2 | 444 | Calithera Biosciences, IncINDUSTRY | 8 | Mar 20, 2023 | clinicaltrials |
| NCT02776644 | Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan | completed | — | 1,349 | PfizerINDUSTRY | 0 | Mar 16, 2023 | clinicaltrials |
| NCT03718754 | En-bloc vs Conventional Resection of Primary Bladder Tumor(eBLOC) | completed | Phase 3 | 384 | David D'AndreaOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04402749 | The Incidence of Pulmonary Embolism During Nephrectomy | completed | — | 416 | Mahidol UniversityOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT03330886 | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina | completed | — | 13 | Hoffmann-La RocheINDUSTRY | 1 | Mar 13, 2023 | clinicaltrials |
| NCT02264548 | A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy | completed | Phase 1 | 14 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT03854721 | A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer | completed | Phase 1 | 6 | Vaxiion TherapeuticsINDUSTRY | 1 | Mar 3, 2023 | clinicaltrials |
| NCT00565903 | Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome(PPB) | completed | — | 1,247 | Ashley HillOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT03063762 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | completed | Phase 1 | 69 | Hoffmann-La RocheINDUSTRY | 9 | Feb 17, 2023 | clinicaltrials |
| NCT05728515 | A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma | completed | Early Phase 1 | 3 | Peking Union Medical College HospitalOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT05729763 | Three-dimensional Virtual Imaging to Improve the Accuracy of Standard CT-based Nephrometric Scores: a Prospective Multicentric Observational Study | completed | — | 300 | San Luigi Gonzaga HospitalOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02217891 | IFACT: Incidental Findings in Advanced Cancer Therapy(IFACT) | completed | — | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT02281383 | Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer | completed | Phase 2 | 80 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03058757 | The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation | completed | Phase 2 | 71 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02420821 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)(IMmotion151) | completed | Phase 3 | 915 | Hoffmann-La RocheINDUSTRY | 21 | Jan 30, 2023 | clinicaltrials |
| NCT04072224 | Evaluation of the Reproducibility of Ablation Volumes at One Month After Microwave Treatment Compared to the Manufacturer's Abacus: on the Kidney, Liver and Lung(Ablation) | completed | — | 60 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03212651 | Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab(PANDORE) | completed | Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT03434132 | Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. | completed | N/A | 116 | Regina Elena Cancer InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04430842 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | completed | Phase 1 | 15 | Quadriga Biosciences, Inc.INDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT03307200 | Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy | completed | — | 90 | University Hospital, GhentOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT04598724 | Addressing Barriers to Palliative Care Use in Bladder Cancer | completed | — | 54 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2023source: clinicaltrials